Clinical Trial Update: The Effects of Eplerenone on Markers of Myocardial Fibrosis in Adult Congenital Heart Disease [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the effect of eplerenone on markers of myocardial fibrosis in adults with congenital heart disease; the study was terminated and result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Single-ventricle Congenital Heart Disease
• Tetralogy of Fallot
• Transposition of the Great Arteries

Drugs mentioned

• eplerenone (eplerenone)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Tetralogy of Fallot, Transposition of the Great Vessels With an Arterial Switch | Phase 4 | Status: TERMINATED | Results posted: 2018-05-04